Mobia Medical 8th Annual Wolfe Research Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. We are live. Good afternoon, everybody. My name is Mike Polark, medical device analyst at Wolfe Research. Welcome to day two of the Wolfe Research Healthcare Conference. Pleased in this session to be joined by Mobia Medical CEO Richard Foust. Richard, welcome to the conference. Thanks for being here. Yeah.
Thank you. Mobia is new to the public markets.
You've been on the journey for some years. I'd love to give you a chance to just introduce Mobia, Vivistim, and what you're building.
Yeah. Thank you. For those who don't know the company, Mobia Medical is really pioneering work for chronic stroke survivors. We're the first company in the U.S. for this huge unmet need, which is stroke recovery. Many of you know people who've had a stroke, and today, in a lot of places, that's where their care ends. We're trying to rewrite the narrative so that in the future, comprehensive stroke centers will really refer to themselves as comprehensive stroke centers, including stroke recovery. What our technology does, it's a vagus nerve stimulator, Class III implantable, and that device essentially rewires the brain and allows for people to have better hand and arm function within a six-week protocol. As I mentioned, it's a huge unmet need.
There has been incredible science that has led to the proliferation of stroke survivors, people surviving a stroke, and a proliferation of those people living in the U.S. today. It is one of the larger unmet needs of disability and cost. There are 9 million ischemic stroke survivors today living with impairments. Our goal is very simple. It is to bridge that gap and to give everyone that would like to have this technology the ability to get better and become the standard of care.
Good setting of the stage. As I look at the journey for Vivistim, it is early. There is a lot of runway. It is local. It is hospital by hospital. I see three major stakeholders, the stroke physicians, the neurologist, the neurosurgeon, the patient and their family, and then rehab specialist. I think you need to work to get engagement from all three to make the concept work. As you commercialize and invest in, engage with these folks to make Vivistim a reality, if you go by the three stakeholders, what is the most common question from all of them, the biggest tension, and what is your answer?
The most common question is, "Why didn't I know about this before?" Honestly, the stakeholders that we are going to and educating about this solution have all been looking for the solution. I will start with the physicians in the hospital. It is the uncomfortable conversation when a neurologist or a neurosurgeon is visiting the family after the stroke survivor has woken up, and it is, "Okay, you are going to be on a journey. You are going to do rehab. Things are going to get better." Then the question is, "Well, Doctor, if I don't get everything back, what is next?" I think for the hospitals that we work with, Vivistim can be that. I think that is changing the entire dynamic. I would say even more so, we will get to it a little bit later on how the guidelines are impacting that.
On the patient side, we did some early research. We have to realize this huge unmet need is really highlighted by symptomatic patients, meaning they had a stroke, they have impairments, they know they had a stroke, and they can see that impairment every day they wake up, all of their friends, all of their family members. What that means is they are actively engaged in finding solutions. We found about 75% of all stroke survivors are actively engaged in finding solutions. Then you have the therapists. Therapists in general, some of the most brilliant caregivers that I have worked with in my career in medical devices, highly educated, and really put the patient first.
And what's amazing is they actually can't believe the outcomes because these PTs and OTs have treated patients sometimes for 10 or 15 years, and it's more maintenance than improvement, but they're still providing a service for that patient because it's motivation, it's about hope isn't lost. But after they've used Vivistim, their entire perspective changes, and they become an advocate. When I think about the challenge that we're facing, honestly, it's awareness. It's that, as you said, we are using a very disciplined and methodical approach in terms of how we are engaging with the care system to make sure that we're creating something that is durable. That's the tension, is that we can't be everywhere at once in order to be a durable business, but our goal obviously is to be the standard of care.
Maybe economically with the provider, what happens? What do they say most commonly when you say, "Well, we have coding and we have payment, and you're going to make money putting in our product"?
Yeah. Is that as equally surprising as the existence of- No one believes it.
Yeah. Right? You have to prove everything.
Even if you are randomized, triple-blinded, sham-controlled study, everyone wants to see it for themselves, and they want to see the payments, and that is fine. We kind of had that playbook in the beginning, and it was just being very humble in the approach, which is getting that cross-functional group together. The surgery is quite straightforward and safe. The patients get better, and then the hospitals get paid. Then all of a sudden, that conversation happens, which we are not there yet, but you have seen this play out with other kind of elective procedures like knees and hips, is when you have all of that alignment moving in the same direction, which is it is good for the patient, it is good for the hospital, it is good for the company, things start moving pretty quickly. I think eventually we will get there.
Obviously some things to do Yep before then.
But I think that is the hope and the focus.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
